438 related articles for article (PubMed ID: 19733976)
1. Clinical pharmacokinetics of tyrosine kinase inhibitors.
van Erp NP; Gelderblom H; Guchelaar HJ
Cancer Treat Rev; 2009 Dec; 35(8):692-706. PubMed ID: 19733976
[TBL] [Abstract][Full Text] [Related]
2. [Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Ding JF; Zhong DF
Yao Xue Xue Bao; 2013 Jul; 48(7):1080-90. PubMed ID: 24133973
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
Scheffler M; Di Gion P; Doroshyenko O; Wolf J; Fuhr U
Clin Pharmacokinet; 2011 Jun; 50(6):371-403. PubMed ID: 21553932
[TBL] [Abstract][Full Text] [Related]
5. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
[TBL] [Abstract][Full Text] [Related]
6. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
Tang SC; de Vries N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2013 Sep; 346(3):486-94. PubMed ID: 23843632
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
8. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Petrelli A; Giordano S
Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
[TBL] [Abstract][Full Text] [Related]
10. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
Hu S; Chen Z; Franke R; Orwick S; Zhao M; Rudek MA; Sparreboom A; Baker SD
Clin Cancer Res; 2009 Oct; 15(19):6062-9. PubMed ID: 19773380
[TBL] [Abstract][Full Text] [Related]
12. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.
Will Y; Dykens JA; Nadanaciva S; Hirakawa B; Jamieson J; Marroquin LD; Hynes J; Patyna S; Jessen BA
Toxicol Sci; 2008 Nov; 106(1):153-61. PubMed ID: 18664550
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Andriamanana I; Gana I; Duretz B; Hulin A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 926():83-91. PubMed ID: 23562906
[TBL] [Abstract][Full Text] [Related]
14. Pharmacy benefit spending on oral chemotherapy drugs.
Curtiss FR
J Manag Care Pharm; 2006 Sep; 12(7):570-7. PubMed ID: 16981802
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
Hu S; Niu H; Minkin P; Orwick S; Shimada A; Inaba H; Dahl GV; Rubnitz J; Baker SD
Mol Cancer Ther; 2008 May; 7(5):1110-20. PubMed ID: 18483300
[TBL] [Abstract][Full Text] [Related]
16. [Focus on GIST management].
Tardieu M; Dômont J; Cioffi A; Bonvalot S; Le Cesne A
Bull Cancer; 2010 Jun; 97(6):723-31. PubMed ID: 20483709
[TBL] [Abstract][Full Text] [Related]
17. Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
Narjoz C; Favre A; McMullen J; Kiehl P; Montemurro M; Figg WD; Beaune P; de Waziers I; Rochat B
PLoS One; 2014; 9(5):e95532. PubMed ID: 24819355
[TBL] [Abstract][Full Text] [Related]
18. [Indications and current development of new targeted therapies in pediatric oncology].
Leblond P; Geoerger B
Bull Cancer; 2011 May; 98(5):527-39. PubMed ID: 21596652
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib and sunitinib.
Kim A; Balis FM; Widemann BC
Oncologist; 2009 Aug; 14(8):800-5. PubMed ID: 19648603
[No Abstract] [Full Text] [Related]
20. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
Deng J; Shao J; Markowitz JS; An G
Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]